Melissa Labonte

Associate Professor at Political Science, Fordham University0 Followers

Dr. Melissa Labonte is an Associate Professor of Political Science at Fordham University in Bronx, NY. She is committed to advancing knowledge in the field of political science, contributing to the academic community through her teaching and research endeavors. While her specific research interests are not detailed, her role at Fordham suggests a focus on educating students and engaging in scholarly activities that enhance understanding of political systems and theories. Dr. Labonte's academic journey and professional experiences reflect her passion for exploring the complexities of political dynamics and fostering critical thinking among her students.

Research Interests

International relations political theory political systems political dynamics

Publications

1 - Abstract A02: Meta-analyses of MPO, EGFR, and GSTM1 genes as risk factors for lung cancer prevention,Cancer Prevention Research

Nick DeVries , S. Pamela Shiao , Melissa J. LaBonte , Ching-Yi Chiu , Linda H. Chiang , Rose Sakamoto ,

, A02-A02, 2012-11-01

2 - Abstract B01: Meta-analyses of MTHFR and UGT1A1 genes as risk factors for colorectal cancer prevention,Cancer Prevention Research

Amanda Lie , S. Pamela Shiao , Melissa J. LaBonte , Ching-Yi Chiu , Linda H. Chiang , Rose Sakamoto ,

, B01-B01, 2012-11-01

3 - Abstract A4: Identification of novel histone deacetylase inhibitor-regulated drug targets and a phase I/II trial of vorinostat in combination with 5-fluorouracil in metastatic colorectal cancer,Clinical Cancer Research

Peter M. Wilson , Melissa J. LaBonte , Anthony El-Khoueiry , Heinz-Josef Lenz , Robert D. Ladner ,

, A4-A4, 2010-04-01

4 - Abstract 1526: Evaluation of the novel tumor suppressor gene, β-Defensin-1, in colorectal cancer cell line models.,Cancer Research

Austin Layton , Pierre O. Bohanes , Wu Zhang , Heinz-Josef Lenz , Melissa J. Labonte ,

, 1526-1526, 2013-04-01

5 - DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines,BMC Medical Genomics

Melissa J LaBonte , Peter M Wilson , William Fazzone , Susan Groshen , Heinz-Josef Lenz , Robert D Ladner ,

, 2009-11-30

6 - Abstract 5438: A novel therapeutic combination with synergistic antitumor activity in colon cancer: The dual tyrosine kinase inhibitor lapatinib and the histone deacetylase inhibitor LBH589,Cancer Research

Melissa J. LaBonte , Peter M. Wilson , Anthony El-Khoueiry , Heinz-Josef Lenz , Robert D. Ladner ,

, 5438-5438, 2010-04-01

7 - Abstract 4213: Evaluation of LMTK3 expression and tumor phenotype in estrogen-dependent colorectal cancer,Cancer Research

Sybil Magturo , Georgios Giamas , Snay Mallick , Austin Layton , Justin Stebbing , Heinz-Josef Lenz , Melissa J. LaBonte ,

, 4213-4213, 2014-10-01

8 - Abstract 1623: The nucleotide metabolizing enzyme dUTPase confers resistance to thymidylate synthase inhibition in non-small cell lung cancer cells,Cancer Research

Peter M. Wilson , Melissa J. LaBonte , Robert D. Ladner ,

, 1623-1623, 2010-04-01

9 - Abstract 1811: Evaluation of anti-CXCR2 small molecule inhibitors as novel chemotherapy targeting the Interleukin-8 pathway in colorectal cancer,Cancer Research

Yinghui Jane E. Huang , Kevin J. Gaffney , Ethan Gerdts , Nicos A. Petasis , Heinz-Josef Lenz , Melissa J. LaBonte ,

, 1811-1811, 2014-10-01

10 - Data from Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer,

Peter M. Wilson , Melissa J. LaBonte , Heinz-Josef Lenz , Philip C. Mack , Robert D. Ladner ,

, 2023-04-03

11 - Data from Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer,

Peter M. Wilson , Melissa J. LaBonte , Heinz-Josef Lenz , Philip C. Mack , Robert D. Ladner ,

, 2023-04-03

12 - Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer,Molecular Cancer Therapeutics

Peter M. Wilson , Melissa J. LaBonte , Heinz-Josef Lenz , Philip C. Mack , Robert D. Ladner ,

, 616-628, 2012-03-01

13 - Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance,Cancers

Shauna McClelland , Pamela J. Maxwell , Cristina Branco , Simon T. Barry , Cath Eberlein , Melissa J. LaBonte ,

, 2797, 2024-08-08

14 - Novel opportunities for thymidylate metabolism as a therapeutic target,Molecular Cancer Therapeutics

Peter M. Wilson , William Fazzone , Melissa J. LaBonte , Jinxia Deng , Nouri Neamati , Robert D. Ladner ,

, 3029-3037, 2008-09-01

15 - Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells,International Journal of Cancer

William Fazzone , Peter M. Wilson , Melissa J. LaBonte , Heinz‐Josef Lenz , Robert D. Ladner ,

, 463-473, 2009-04-21

16 - The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN‐38,International Journal of Cancer

Melissa J. LaBonte , Philipp C. Manegold , Peter M. Wilson , Will Fazzone , Stan G. Louie , Heinz‐Josef Lenz , Robert D. Ladner ,

, 2957-2969, 2009-08-08

Share Melissa's Profile